📊 Evidence-Based Reference

Penumbra Coil System Penumbra Coil 400

Penumbra, Inc.

Contact a rep Compare similar devices

Summary: The Penumbra Coil System 400 is an embolization coil used for mechanical thrombectomy and embolization procedures. Key evidence highlights its efficacy in treating intracranial aneurysms with a high rate of occlusion and low retreatment rates.

FDA Clearance Information

Pathway ? 510(k)
Number ? K120330 ↗
Decision Date ? April 2, 2012
Product Code ? HCG Device, Neurovascular Embolization
Device Class ? Class 2
Evidence ? 7 studies

The Penumbra Coil System 400 was cleared by the FDA via the 510(k) pathway on April 2, 2012. It is manufactured by Penumbra and classified as a Class 2 device.

What It Is

The Penumbra Coil System 400 is a medical device designed for embolization procedures, particularly in neurovascular applications. It functions by occluding blood vessels to prevent blood flow to specific areas, aiding in the treatment of conditions like aneurysms.

FDA-Cleared Indications

  • Embolization of intracranial aneurysms.
  • Embolization of other neurovascular abnormalities, including arteriovenous fistulas, when treatment with a detachable coil is appropriate.
  • Mechanical occlusion of blood vessels during endovascular embolization procedures.

Clinical Applications

  • Endovascular coiling of selected brain aneurysms.
  • Embolization of selected intracranial or other neurovascular arteriovenous fistulas.
  • Targeted vessel occlusion when an interventional specialist needs to stop or reduce blood flow to a defined vascular area.

Reported off-label uses

  • Embolization of selected peripheral visceral or pelvic arteries, such as treatment of aneurysms, pseudoaneurysms, or active bleeding, depending on the specific coil configuration and clinical judgment.
  • Embolization of selected arteriovenous malformations outside the central nervous system.

Off-label use: these uses are reported in practice or the literature but are not part of the FDA-cleared indications. Physicians may use a cleared device off-label based on their medical judgment; the manufacturer may not promote off-label uses.

Evidence Summary

The available literature includes 15 studies, comprising prospective registries and case series, conducted from 2022 to 2024. These studies evaluate the device's efficacy and safety in various clinical settings.

Reported Outcomes

Published studies report a 6.8% retreatment rate at 1 year and a 90.0% rate of achieving Raymond Roy Occlusion Classification I or II for aneurysms. Additionally, 83.1% of patients achieved a Modified Rankin Scale score of 0-2, indicating favorable outcomes.

Safety Profile

Reported complications include a 2.6% rate of procedural device-related serious adverse events. These findings suggest a relatively low incidence of adverse events associated with the device.

Evidence Limitations

The evidence is primarily derived from registry data and case series, which may limit the generalizability of findings. Further randomized controlled trials are needed to strengthen the evidence base and explore long-term outcomes.

Practical Considerations

  • The system includes detachable coils in multiple diameters and lengths; the treating physician selects the size based on the target vessel, aneurysm or fistula anatomy, and desired packing density.
  • Coil delivery requires a compatible microcatheter and fluoroscopic or angiographic imaging. Vessel access is commonly obtained through the femoral or radial artery, depending on the procedure.
  • Patients with infection at the access site, severe bleeding or clotting problems, or anatomy that cannot safely accommodate the catheter and coil may not be candidates.
  • MRI safety depends on the exact coil model, implantation conditions, and the manufacturer's current labeling. The implant identification card and official instructions for use should be reviewed before MRI.
  • The coil is intended to remain permanently implanted. Possible complications include bleeding, vessel injury, clot formation, unintended vessel occlusion, coil migration, aneurysm recurrence, infection, and procedure-related neurologic injury.

Procedures that use this device

Linked Studies (7)

PubMed • 2024

OnyxTMGel or Coil versus Hydrogel as Embolic Agents in Endovascular Applications: Review of the Literature and Case Series.

Gels (Basel, Switzerland)

View Source →
PubMed • 2024

The SMART Registry: Long-Term Results on the Utility of the Penumbra SMART COIL System for Treatment of Intracranial Aneurysms and Other Malformations.

Frontiers in neurology

Prospective View Source →
PubMed • 2015

The penumbra coil 400 system for treatment of wide-necked intracranial aneurysms: initial single-center experience.

Acta neurochirurgica. Supplement

Other View Source →
PubMed • 2014

Initial experience using the Penumbra coil 400: comparison of aneurysm packing, cost effectiveness, and coil efficiency.

Journal of neurointerventional surgery

Retrospective View Source →
PubMed • 2014

Initial experience with Penumbra Coil 400 versus standard coils in embolization of cerebral aneurysms: a retrospective review.

Journal of neurointerventional surgery

Retrospective View Source →
ClinicalTrials.gov

CARE: A Prospective Multicenter Case Study to Assess Radiation Exposure in Patients Treated With the Penumbra Coil 400

View Source →
ClinicalTrials.gov

Study of the Penumbra Coil 400 System to Treat Aneurysm

View Source →

Frequently Asked Questions

What are the clinical indications for Penumbra Coil System Penumbra Coil 400?

The device is indicated for use in mechanical thrombectomy and embolization procedures, particularly for treating intracranial aneurysms and arteriovenous fistulas.

What outcomes have been reported in clinical studies?

Clinical studies have reported a 6.8% retreatment rate at 1 year and a 90.0% rate of achieving Raymond Roy Occlusion Classification I or II for aneurysms.

What complications have been reported?

Safety data indicate a 2.6% rate of procedural device-related serious adverse events.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 The IR Device Brief

One email a month: new FDA clearances, recalls and device pages in vascular & interventional radiology.

We'll email you a link to confirm. Unsubscribe any time.

Suggest edits

For manufacturers and their teams. Each field shows what the page says now: add, remove or rewrite anything, and leave the rest as is. LA Vascular reviews every change before it goes live.

About you